Physician profile
Robert H Squire
NPI 1750310082
$3,106.38
in general payments reported to CMS, 2019-2025
32 companies · $665 in 2025
The $665 reported for 2025 was more than what 79% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $233 · 2020: $118 · 2021: $379 · 2022: $479 · 2023: $425 · 2024: $808 · 2025: $665.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,899.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,898.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $941.89 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $275.61 | 2021-2025 | Vraylar |
| Lilly USA, LLC | $274.09 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $259.03 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Pfizer INC. | $228.34 | 2020-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $213.16 | 2022-2025 | Xifaxan, Trulance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $182.28 | 2021-2025 | Jardiance |
| Novartis Pharmaceuticals Corporation | $81.17 | 2019-2020 | |
| Biohaven Pharmaceutical Holding Company LTD. | $77.14 | 2022 | |
| Abbott Laboratories | $69.82 | 2022-2024 | Freestyle Libre 3 |
| Dexcom, INC. | $53.42 | 2024-2025 | Dexcom G6 Transmitter |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $49.36 | 2024-2025 | Caplyta |
| Bayer Healthcare Pharmaceuticals INC. | $36.52 | 2021 | |
| Sunovion Pharmaceuticals INC. | $31.50 | 2019 | |
| Amgen INC. | $30.96 | 2020-2023 | Repatha, Otezla |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $29.28 | 2021-2024 | Veozah |
| Lundbeck LLC | $24.21 | 2024 | Rexulti |
| Exact Sciences Corporation | $22.49 | 2025 | The Cologuard Plus Collection Kit |
| Inspire Medical Systems, INC. | $22.47 | 2024 | Inspire |
| Ucb, INC. | $22.08 | 2022 | |
| Corcept Therapeutics | $20.02 | 2025 | Korlym |
| Amarin Pharma, INC. | $19.62 | 2022 | |
| Sumitomo Pharma America, INC. | $17.78 | 2025 | Gemtesa |
| Shire North American Group INC | $15.73 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $14.61 | 2024 | Eliquis |
| Sanofi Pasteur INC. | $14.55 | 2023 | |
| Cranial Technologies, INC | $14.28 | 2019 | |
| Allergan, INC. | $14.27 | 2020 | |
| Avanir Pharmaceuticals, INC. | $13.53 | 2019 | |
| Watermark Medical, INC. | $13.22 | 2024 | |
| Janssen Pharmaceuticals, INC | $12.34 | 2019 | |
| Sanofi-Aventis U.S. LLC | $11.61 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Squire listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.